Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07175285 · ClinicalTrials.gov registry record

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

A clinical trial of Systemic Lupus Erythematosus (SLE), sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
223
Enrollment target
20
Study locations

NCT07175285: Recruiting study of Systemic Lupus Erythematosus (SLE), sponsored by Bristol-Myers Squibb.

NCT07175285 is a study of Systemic Lupus Erythematosus (SLE) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 223 participants, below the 1,049-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07175285, a study of Systemic Lupus Erythematosus (SLE), is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
223 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

Interventions

  • DRUG Current standard of care treatment options

Study Locations (20)

Florida

  • Local Institution - 0063 - Fort Lauderdale
  • Local Institution - 0061 - Hollywood
  • LIFE Clinical Trials - Margate
  • Local Institution - 0068 - Palm Beach Gardens

California

  • Local Institution - 0054 - La Jolla
  • Local Institution - 0001 - La Palma
  • Rheumatology Center of San Diego - San Diego

Michigan

  • Local Institution - 0034 - Ann Arbor
  • AA MRC - Grand Blanc

North Carolina

  • DJL Clinical Research, PLLC - Charlotte
  • Local Institution - 0037 - Durham

Arizona

  • Local Institution - 0062 - Mesa

Illinois

  • Local Institution - 0065 - Willowbrook

Maryland

  • Local Institution - 0064 - Rockville

New Jersey

  • Local Institution - 0060 - West Long Branch

Trial Details

FieldValue
Enrollment Target 223 participants
Start Date 2025-10-08
Est. Completion 2032-11-01
Bristol-Myers Squibb

1,025 total trials

What NCT07175285 shows while recruiting

NCT07175285 is an observational study that tracks outcomes without assigning an intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap, below the 1,049-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention - of which Current standard of care treatment options is the first listed.

NCT07175285 names 20 study sites across 13 states, led by Florida, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT07175285 about?

NCT07175285 is a clinical study titled "A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants". The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

What is the current status of trial NCT07175285?

This trial is currently recruiting. The enrollment target is 223 participants. The study started on 2025-10-08. Estimated completion is 2032-11-01.

What conditions does trial NCT07175285 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE).

What interventions are being tested in trial NCT07175285?

The interventions under investigation include: Current standard of care treatment options (DRUG).

Who is sponsoring clinical trial NCT07175285?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07175285 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Systemic Lupus Erythematosus (SLE)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07175285's enrollment target sits among peer trials

223 5th of 14 higher than 10 of 14 other Systemic Lupus Erythematosus (SLE) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus (SLE) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06640803 · 223 participants · NA

    Sacramento Clinical High Risk for Psychosis Stepped-Care Program

  • NCT07205718 · 223 participants · Phase 1

    A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

  • NCT02706561 · 224 participants · NA

    Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

  • NCT04140344 · 224 participants · NA

    The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07175285, the US trial registry maintained by the National Library of Medicine. NCT07175285 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.